Tazemetostat Pill

Phase 2Small molecule

WWeill Medical College of Cornell University

Tazemetostat Pill is one of 87 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

Follicular LymphomaRecruiting

LymphomaPhase 1

Recruiting

Follicular LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Cabenuva

GSK

Preclinical

1 3

Norvir

AbbVie

Preclinical

1 4

Tazemetostat Pill

WWeill Medical College of Cornell University

Phase 2

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Prostate Cancer

NCT04812366

Q3 2031

Phase 1Recruiting

Lymphoma

NCT05934838

Q4 2033

Phase 2Recruiting

Follicular Lymphoma

NCT05994235

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT05934838·15 enrolled

Follicular Lymphoma1 trial

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT05994235·50 enrolled

Prostate Cancer1 trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting·UUniversity of British Columbia·Phase 2·NCT04812366·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tazemetostat Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tazemetostat Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tazemetostat Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWeill Medical College of Cornell University

Tazemetostat Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2031

Q4 2033

Trials by Indication[1]

Lymphoma1 trial

Follicular Lymphoma1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News